A detailed history of Graham Capital Management, L.P. transactions in Veracyte, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 17,571 shares of VCYT stock, worth $684,214. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,571
Holding current value
$684,214
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.0 - $35.25 $368,991 - $619,377
17,571 New
17,571 $597,000
Q1 2024

May 15, 2024

BUY
$21.0 - $29.1 $259,560 - $359,676
12,360 Added 41.02%
42,490 $941,000
Q4 2023

Feb 14, 2024

BUY
$19.72 - $28.68 $77,775 - $113,113
3,944 Added 15.06%
30,130 $828,000
Q3 2023

Nov 22, 2023

BUY
$22.33 - $29.92 $584,733 - $783,485
26,186 New
26,186 $584,000
Q3 2022

Nov 14, 2022

BUY
$16.58 - $27.9 $418,081 - $703,526
25,216 New
25,216 $418,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.79B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.